For example, abatacept in CTLA4 haploinsufficiency, LRBA and DEF6 deficiencies; tocilizumab in STAT3 GOF; JAK inhibitors in STAT3 and STAT1 GOF patients; alemtuzumab for CD25 deficiency; PIK3δ inhibitors for APDS or anti-TNFα therapy for vasculitis in ADA2 deficiency (Table 1). This evidence concerns the gene IL2RA and vasculitis.